Insights

This paper highlights macro and micro factors affecting oncology and proposes a partnership-driven framework to catalyze innovation for oncology-focused biopharma – as well as the role that select high-impact technologies will have on the on the entire value-chain of cancer research and care delivery. 

Patient monitoring is an inherent part of patient management. Intermittent and continuous measurements have a range of uses, from defining disease states and characterising progression to informing therapeutic approaches and...

The rapid, at home COVID-19 antigen test from digital diagnostics company Ellume features core technology from Cambridge Consultants. Read how this FDA approved test is set to be a game-changer in the global pandemic.

Dan Cowen, Senior Consultant at Cambridge Consultants, presented at Drug Delivery to the Lungs (DDL) - Christmas Lectures and talked about the path to a sustainable future for inhalation products. Watch his presentation to learn how sustainability in inhalation products can be achieved whilst maintaining safety and efficacy at the core.

Sustainability emerged as a hot and emotive topic at this year’s Drug Delivery to the Lungs (DDL) conference, read Donal Taylor's thoughts on other key trends that emerged.

Matt Garwood challenges the medical device development status quo. If we embrace a bold, comprehensive response that begins at the concept stage and ends with the device user, it is possible to challenge conventional thinking and change for the better.  

People with diabetes have an increased risk of developing serious health problems, including neuropathy. We’ve developed an AI-based system, in partnership with eminent specialists, to assess the presence of neuropathy from retinal images.

The next step in the fight against coronavirus looks set to be mass screening of whole cities and towns. Symon Cotton, Head of Life Sciences at Cambridge Consultants, believes that so-called multipool screening could make all the difference to the success of this approach during the current second wave of the virus.

Metered-dose inhalers account for 3.5% of the UK National Health Service’s carbon footprint and are tagged as a carbon hotspot. But there is no reason that sustainability has to come at the cost of clinical benefit. 

Symon Cotton explores the use of pooled testing techniques for deploying mass Covid testing.  

In September the UK government announced Operation Moonshot – to deliver the mass screening of 10 million samples for COVID-19 every day. Andrew Goulter takes a pragmatic look at five key areas of focus if we are to increase screening efficiency and capacity. 

Ryan Chaves explores some of the approaches currently being used – or considered – to address concerns over the cybersecurity of implanted medical devices.